Baxter International Inc (BAX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

Total Cash From Operating Activities Chart for Baxter International Inc

Baxter International Inc (BAX) operating cash flow for FY2025 was USD 845.0M, a -17.1% change from FY2024. Baxter International Inc's operating cash flow grew from USD 463.0M in 1985 to USD 845.0M in 2025 (82.5% over 40 years). Operating cash flow compound annual growth rate: 5-year CAGR of -14.7%, 10-year CAGR of -7.1%, 20-year CAGR of -3.0%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$12.15B
Implied Share Price
$23.50
Enterprise Value
$20.68B
Revenue (TTM)
$11.47B
EBITDA
$1.88B
Profit Margin
-9.27%
Trailing P/E
—
Forward P/E
12.45
Price/Book (MRQ)
2.12
Price/Sales (TTM)
1.06
EV/EBITDA
27.14
EV/Revenue
1.80
Dividend Yield
0.00%
Book Value
$11.92
Free Cash Flow (FY2025)
$323.00M
Free Cash Flow Yield
2.66%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.